Summary & Overview
HCPCS Level II J0162: Epinephrine (Fresenius) Injection, 0.1 mg
HCPCS Level II code J0162 denotes a 0.1 mg injection of epinephrine (Fresenius), identified as not therapeutically equivalent to J0165. This code captures a specific small-dose epinephrine product used in acute care and outpatient settings for management of severe allergic reactions and other indications requiring parenteral epinephrine. Nationally, accurate coding for epinephrine products affects clinical documentation, inventory controls, and payer adjudication for emergency and ambulatory medication services.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context, common sites of service, and the distinctions from therapeutically non-equivalent epinephrine products. The publication summarizes available benchmarks and policy-relevant points that influence coverage and billing for small-dose injectable epinephrine, and outlines items for billing staff and revenue cycle teams to confirm during claims submission.
This material is designed for a national audience and focuses on coding clarity, clinical applicability, and payer coverage considerations rather than state-specific rules.
Billing Code Overview
HCPCS Level II code J0162 represents an injection of epinephrine (Fresenius), 0.1 mg, specifically noted as not therapeutically equivalent to J0165. This product is a single-dose injectable formulation of epinephrine used for emergency treatment of severe allergic reactions and other indications where a measured small dose of epinephrine is required.
Service type: injectable drug administration
Typical site of service: outpatient clinic, emergency department, physician office, or other outpatient settings where parenteral medications are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A child or adult presents to an outpatient clinic, urgent care, emergency department, or physician office with an acute anaphylactic reaction or high-risk allergic exposure (for example, after insect sting, food ingestion, medication exposure, or severe allergic rhinitis with respiratory compromise). The clinician evaluates airway, breathing, circulation and documents signs such as hives, angioedema, bronchospasm, stridor, hypotension, or altered mental status. When immediate intramuscular epinephrine is indicated, a clinician or trained staff prepares a 0.1 mg dose of epinephrine (compound vial labeled as fresenius, not therapeutically equivalent to J0165) and administers via intramuscular injection (typically mid-anterolateral thigh). Vital signs and response to medication are monitored, and additional emergency treatments (oxygen, nebulized bronchodilator, intravenous fluids, antihistamines, corticosteroids) are provided as clinically indicated. The medication administration, drug lot, concentration, route, site, and patient response are documented in the medical record. Typical sites of service include ambulatory clinic, urgent care center, emergency department, and physician office immunology/allergy or primary care visits where acute allergic reactions are treated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure |